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Introduction
Pepsinogen I and II, as precursors of pepsin, are produced by gastric mucosa and released into the gastric lumen and pe-
ripheral circulation.1 The advanced inÀammation of gastric 
mucosa and its progression toward atrophic gastritis (AG) in the 
corpus is associated with a change in serum biomarkers pepsino-
gen I and II; atrophy of corpus mucosa leads to low synthesis of 
pepsinogen I and a low release of pepsinogen I into the serum. 
Advanced gastric atrophy and hypo- or achlorhydrias are associ-
ated with very low levels of pepsinogen I in contrast to pepsino-
gen II, which remains elevated in serum.2,3 During the last decades 
following the introduction of these biomarkers there has been ex-
tensive research, particularly in Japan which has used these serum 
biomarkers for the early detection of gastric cancer (GC).4–6 In a 
large population-based study in Japan, Miki et al., have found that 
80% of all early GC detected by routine endoscopy had a level of 
serum pepsinogen I less than 70 g/mL combined with a Pepsino-
gen I to II ratio of less than 3.7      
We have previously reported that pepsinogen II is a good marker 
for the diagnosis of any type of gastritis in that it can differentiate 
between subjects with gastritis from those with normal mucosa. 
Additionally, the progression of gastritis to AG and pangastritis is 
associated with a continual increase in serum pepsinogen II levels, 
whereas the levels of pepsinogen I in the early stage of AG remain 
unchanged and are normal.8 
The end stages of advanced AG causing by H. pylori infection 
is severe reversible by H. pylori eradication.9,10 Thus, gastritis in 
patients at risk for GC is treatable, in the absence of pre-existing 
precancerous conditions such as mucosal atrophy and intestinal 
metaplasia. For the purpose of GC prevention by mass eradica-
tion, the selection of infected subjects without advanced AG in 
high risk areas, namely those who present with high pepsinogen 
II and normal pepsinogen I levels in their sera, seems to be im-
portant.        
In Northern Iran, Ardabil is considered a high risk area for GC; 
conversely, the central areas of Yazd and its neighboring province 
Kerman are both areas that have low rates of GC.11 Therefore, the 
purpose of this study is to evaluate the pattern of serum pepsino-
gens I and II and their potential to verify the proportion of patients 
with no advanced AG in three cities (Ardabil, Kerman, and Yazd) 
that have different GC rates.
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Materials and Methods
Healthy blood donors over the age of 20 years in three cities (Ar-
dabil, Yazd, and Kerman) were the target populations during 21st 
March, 2008 – 21st March, 2009. We also included 81 symptomat-
ic GC patients (56 males and 25 females) whose mean age was 65 
± 10.9 years in this study. Most had advanced GC.  Blood samples 
were obtained from each subject by voluntary blood donation. 
The sera were frozen and kept at -80 until analysis. We planned 
to collect sera from 150 subjects in each city; 30 from each decade 
of life, beginning from age 20 up to 60 years. However due to the 
lack of adequate numbers of subjects older than 60 years in the 
blood transfusion centers, therefore we chose 30 persons over the 
age of 60 years in each city from a non-gastroenterology hospital 
ward, mainly from the hospitals’ orthopedic wards. In the main 
university hospitals of all three capital cities, the diagnosis of all 
subjects undergoing upper gastrointestinal (GI) endoscopies dur-
ing a one year period (21st March, 2008 until 21st March, 2009) 
was veri¿ed. Blood donors’ sera were analyzed for pepsinogen I 
and II (ELISA Kits, Biohit, Helsinki, Finland) and H. pylori IgG 
antibody titer (Trinity Company, Italy) by ELISA. The sera were 
considered positive for H. pylori when the color extinction was 
1.1 or equivocal (0.9 and 1) and negative when the extinction 
was <0.9 according to the manufacturer’s instructions. The num-
ber of subjects needed for the study was calculated on the assump-
tion that the prevalence of AG in adults from Ardabil was more 
than 15%12 and in the city of Kerman or Yazd, it was less than 5%. 
By a power of 90% and ȕ of 0.10, we needed at least 120 cases 
in each city. We decided to enroll 150 subjects. In addition, to 
evaluate the severity of precancerous conditions associated with 
GC in the high risk area, blood samples were taken from patients 
diagnosed with GC, as veri¿ed by endoscopy and histologic ex-
amination in the city hospital of Ardabil. All GC patients were 
symptomatic and had advanced GC. The majority had not under-
gone surgery.
Statistical analysis was performed with SPSS version 16, mean 
± SD, 95% con¿dence interval (CI) and t-test. P < 0.05 was con-
sidered signi¿cant. Information about the cancer incidence was 
obtained from either the literature or the Cancer Registries of the 
Iranian Ministry of Health and Education (MHD). The Iranian 
Cancer Registry was established in 1995 in collaboration with the 
International Agency for the Research of Cancer (IARC). The Ira-
nian Parliament established a law that required all physicians and 
pathology centers to report all cancer cases to MHD. The Cancer 
Registry information is published annually in Farsi in a Cancer 
Registry book, of which the latest one is from 2007.
Results
There were 449 subjects (83 females and 366 males) whose 
mean age was 45 ± 15 years (19–86 years). The number of sub-
jects and their mean ages in the three cities was identical. There 
were no differences in the means of pepsinogen I and II between 
males and females; the concentration of pepsinogen I amongst 
males was 107.8 ± 42 g/mL (95% CI: 103–112) and amongst 
females, 96 ± 55 g/mL (95% CI: 85–107). The levels of pep-
sinogen II among males was 7.4 ± 4.4 g/mL (95% CI: 7–7.9) and 
among females, 8.8 ± 6.1 g/ml (95% CI: 7.5 – 10.1). 
The serum levels of pepsinogen I and II, the ratio of pepsinogen 
I to II and the H. pylori infection rate in each city as well as the 
percentages of those with low pepsinogen I (<25 g/mL) and the 
percentages of those with a combination of low pepsinogen I and 
low pepsinogen I to II ratio (<3 or <5) are presented in Table 1. 
There was no signi¿cant difference in the serum levels of pepsino-
gen I and II between the three cities. The mean pepsinogen I to II 
ratio was signi¿cantly less in Ardabil than in Yazd and Kerman. 
Few subjects had a pepsinogen I to II ratio less than 5 in Ardabil 
and Kerman, while no subject had a pepsinogen I to II ratio less 
than 5 in Yazd. The H. pylori infection rate was higher in the city 
of Yazd compared to the other cities. When the study population 
was classi¿ed into age groups of 10 year intervals, we noted a 
trend of decreasing pepsinogen I and increasing pepsinogen II 
levels with advancing age. Pepsinogen II levels were signi¿cantly 
higher in the age groups over 30 years when compared to those 
less than 30 years (Table 2). The pepsinogen I to II ratio decreased 
with age and the means were signi¿cantly less among those over 
the age of 50 years when compared to those less than age 40 years. 
Serum pepsinogen II levels in subjects with H. pylori infection 
was signi¿cantly higher (8.5 ± 4.8 vs. 6.5 ± 4.6g/mL, P < 0.05) 
and the pepsinogen I to II ratio was lower (15 ± 7.5 vs. 21.6 ± 16.4 
g/mL, P < 0.01).  However, the mean pepsinogen I levels did not 
differ between infected (106 ± 41 g/mL) and uninfected subjects 
**Cities Kerman Yazd Ardabil
Number 152 148 149
Age (years) 45 ± 14 45 ± 14 45 ± 15
Male/female 105/47 129/17 130/19
Pep***  I (g/mL) 103.3 ± 49.8(95%CI: 95–111)
111.7 ± 39
(95% CI: 105–118)
102.5 ± 42.6
(95% CI: 95–109)
Pep II (g/mL) 7.5 ± 5.3(95% CI: 6.7–8.4)
7.6 ± 4.4
(95% CI: 6.9–8.3)
8.1 ± 4.7
(95% CI: 7.3–8.9)
Pep I/II ratio 18.1 ± 12.2(95% CI: 16.2–20.1)
19.1 ± 14.8
(95% CI: 16.7–21.5)
15.1 ± 7.6*
(95% CI: 13.9–16.4)
H. pylori infection rate (%) 55%(95% CI: 47.3–63)
73%**
(95% CI: 66.1–81.3)
61%
(95% CI: 53.1–68.7)
Pep I/II ratio  3 3/152 (1.9%) 0/148 2/149 (1.3%)
Pep I  25 (g/mL) 2/152 (1.3%) 1/148 (0.6%) 3/149 (2%)
Pep I  25 (g/mL) and ratio  3 2/152 (1.3%) 0/148 1/149 (0.6%)
Pep I  70 (g/mL) and ratio  5 4/152 (2.6%) 0/148 5/149 (3.3%)
*Signi¿cant compared to Yazd Province; **Signi¿cant compared to Kerman (P < 0.001) and Ardabil (P < 0.05); ***Pep = pepsinogen.
Table 1. Serum level of biomarkers and H. pylori infection rates among the studied population.
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(104 ± 49 g/mL). The percentage of subjects with pepsinogen I 
levels < 25 g/mL alone or in combination with pepsinogen I to II 
ratios less than 5 or 3, or the percentage of those with pepsinogen I 
levels <70 g/mL in combination with pepsinogen ratio I to II <5, 
as a sign of severe stage advanced AG13,14 were low and did not 
differ among the three populations.  The diagnoses of all patients 
who underwent upper GI endoscopies in the main hospitals of the 
three cities and the incidences of GC for males and females during 
the study period are given in Table 3.
The levels of pepsinogen I, pepsinogen II and pepsinogen I to II 
ratio in the sera of 81 GC patients and their relation to histological 
type and the localization of tumor in stomach as well as the num-
ber of subjects with low pepsinogen I alone or combined with low 
pepsinogen I to II ratio are given in Table 4. The serum levels of 
pepsinogen I and II were not different between two types of GC 
and those with different localization in the stomach. Twelve point 
three percent (12.3%) of GC patients had signs of very advanced 
of atrophic gastritis and 48.1% of them had any type of  AG. This 
means that more than half of the GC patients in Ardabil had no 
AG according to the levels of the serum biomarkers.            
The city of Ardabil had the highest rate of GC and gastric ulcers 
compared to Kerman and Yazd. The rate of GC among all subjects 
who underwent endoscopies in Ardabil was 4 times higher than 
Kerman and 9 times higher than Yazd. According to the Cancer 
Registry data of the Ministry of Health, the ASR/100.000 for GC 
in Ardabil is 49.1 for males and 21.5 for females. In Kerman, the 
rate is 10.2 for males and 5.1 for females.11,15 The ASR/100.000 
for GC in Yazd is 8.35 for males and 6.75 for females during 2006 
– 2007.16
                                                                                                                    
Age group
(years)
20–29
(N = 83)
30–39
(N = 85)
40–49
(N = 97)
50–59
(N = 83)
>60 
(N = 101)
Pepsinogen I 
(g/ml) 
 130 ± 49.8*
 (95% CI:119–140)
105 ± 38
(95% CI: 97–113)
99 ± 32
(95%CI: 92–105)
93 ± 36
(95% CI: 85–101)
102 ± 52 
(95% CI: 91–125)
Pepsinogen II 
(g/ml) 
5.5 ± 3.9*
(95% CI: 4.7–6.3)
7.6 ± 4.4
(95% CI: 6.7–8.6)
7.9 ± 4.4
(95% CI: 7–8.8)
7.7 ± 3.7 
(95% CI: 6.9–8.6)
9.4 ± 6
(95% CI: 8.1–10.6)
Pepsinogen I/II 
ratio
31.4 ± 18.9*
(95% CI: 27.3–35.6)
16.9 ± 8.1**
(95% CI: 15.2–18.7)
14.8 ± 6.3
(95% CI: 13.5–16.1)
7.7 ± 3.7
(95% CI: 6.9–8.6)
9.3 ± 6.1
(95% CI: 8.1–10.6)
*Signi¿cant compared to all other age groups (P < 0.01); **Signi¿cant compared to age groups 20–29 and more than 50 years (P < 0.05).  
Table 2.  Serum pepsinogen levels and ratio of pepsinogen I/II in Ardabil, Kerman, and Yazd according to age groups 
(means, SD and 95% con¿dence intervals).
Cities Kerman Yazd Ardabil
Upper GI endoscopies (N) 2306 2027 2217
Male/female 1095/1211 1140/887 1090/1127
Duodenal ulcer 151 (6.5%) 197 (9.7%) 115 (5.1%)
Gastric ulcer 67 (2.9%) 34 (1.6%) 159 (7.1%)
Gastric cancer (GC)
Age (years)
Male/female
46 (1.9%) 20 (0.9%) 192 (8.7%)* 
60 ± 16 69 ± 16 66 ± 4.5
30/14 16/4 127/65
Esophageal cancer 15 (0.65%)  28 (1.3%)  35 (1.5%)
*P < 0.0001 compared to other cities.
Table 3.  Relevant ¿ndings from upper gastrointestinal (GI) endoscopies conducted in the main university hospitals in Kerman,
 Yazd, and Ardibil during 2008.
Pep I <70 g/L & 
Pep ratio <5
N (%)
Pep I <25 g/L 
& Pep ratio <5
N (%)
Pep I <25 g/L
N (%)Pep I/II ratioPep II (g/L) *Pep I (g/L) * 
23 (48.9%)6 (12.8%)7 (14.9%)3.8 ± 2.426.2 ± 18.292.8 ± 79.15IntestinalN = 47Histologic 
type of gastric 
cancer (GC) 16 (47.1%)4 (11.8%)4 (11.8%)4.2 ± 324.2 ± 17.892.8 ± 90.3Diffuse N = 34
7 (50%)1 (7.1%)1 (7.1%)4.3 ± 3.326.2 ± 18.386.7 ± 54.95
Mostly 
proximal
N = 14
Tumor 
localization 18 (54.5%)4 (12.1%)4 (12.1%)3.6 ± 2.623.8 ± 16.575.7 ± 63
Mostly 
middle
N = 33
14 (41.2%)5 (14.7%)6 (17.6%)4.25 ± 2.426.5 ± 19.6111.9 ± 105.7
Mostly 
distal
N = 34
39 (48.1%)10 (12.3%)11 (13.6%)4 ± 2.625.4 ± 17.992.8 ± 83.5Total (n = 81)
*(Mean ± 1SD)
Table 4. Serum biomarkers pepsinogen I, pepsinogen II and pepsinogen I/II ratio in 81 patients with gastric cancer (GC) from Ardabil in relation to 
tumor histologic type and localization.
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Discussion
H. pylori infection plays a pivotal role in the development of 
gastritis and its advanced type AG. GC may develop in the ma-
jority of cases as a result of AG under the inÀuences of various 
genetic end environmental factors.17 A recent meta-analysis study 
has shown long-term reduction of GC following the eradication 
of H. pylori in comparison with a control group.18 The prevention 
of GC is probably an achievable goal with the eradication of H. 
pylori infection and is indicated in those areas with high an inci-
dence of GC, as recommended by Asian guidelines.19 However, 
few individuals infected with H. pylori develop GC. Therefore, 
mass eradication of H. pylori infection in at risk population can 
bene¿t only a small number of susceptible patients. Mass eradica-
tion of H. pylori is not advantageous for a substantial part of those 
who do not develop GC and may cause patients to suffer from the 
side effects of therapy as well as the potential for development 
of bacterial resistance, in addition to causing an additional ¿nan-
cial burden for the society. Among the population at risk, we must 
therefore select those affected by pangastritis or predominant cor-
pus gastritis who present with either no atrophy or less advanced 
atrophy and/or no intestinal metaplasia. Serum biomarkers are 
suitable for selecting that proportion of the population character-
ized by a normal pepsinogen I level with no sign of advanced 
atrophy but with a remarkable increase of serum pepsinogen II as 
a sign of diffuse gastritis or pangastritis.8 
Advanced AG is reported to be very common in countries that 
have a high GC prevalence. In a comparative study with age-
matched consecutive patients from the endoscopy units of Leeds 
and Tokyo, it has been shown that the Japanese subjects had prev-
alent, more severe gastritis and more predominant corpus gastritis 
than those from the United Kingdom.20 In Portugal, which has a 
high GC prevalence, the rate of endoscopically diagnosed AG is 
36.3%, while it is 8.3% in Mozambique that has a low prevalence 
of GC, although the rate of H. pylori infection is high in both 
countries.21,22  
In Iran, as shown in our study, GC was diagnosed four and nine 
times more in the endoscopy unit of Ardabil compared to Kerman 
and Yazd, respectively, during a one year period. The endoscopy 
units of the hospitals in all three cities are the largest endoscopy 
units in these capital provinces, where the majority of middle and 
lower economic status patients are referred for endoscopic proce-
dures. According to the Cancer Registry of these provinces, 11,15 
the GC incidence is four times greater in Ardabil than Kerman 
and Yazd. These differences in GC incidence should be associated 
with a different prevalence of AG in these cities.
The mean levels of pepsinogen I and II did not differ amongst 
populations of the same mean ages in Ardabil, Kerman and Yazd, 
although the prevalence of GC was remarkably high in Ardabil.12 
No corresponding studies exist from other cities concerning the 
prevalence of AG. In all Iranian provinces, the H. pylori infection 
rate is high and not related to areas that have a high prevalence of 
GC.23–24  
Serum pepsinogen I levels were higher in the age group less than 
30 years compared with those in older groups. The pepsinogen 
II levels have shown a trend toward a non-signi¿cant increase 
and the pepsinogen I to II ratio to a signi¿cant decrease in Ard-
abil when compared to Kerman and Yazd. It seems that each of 
the two serum biomarkers alone or their combination with a low 
pepsinogen I to II ratio is not sensitive enough to diagnosis AG. 
However, the ratio can show the trend of progression of gastritis 
with increasing age. Our results contradict the results by Stem-
mermann et al. who have reported a fourfold higher rate of low 
pepsinogen I levels in the sera of Japanese subjects to Hawaiian 
subjects of the same age.25 The Japanese population was shown 
to have a fourfold higher incidence of GC when compared to the 
Hawaiian population. However, the number of subjects studied in 
Hawaii (n = 43) was lower than in Japan (n = 150).  Additionally, 
the sensitivity of the pepsinogen I measured by radioimmunoas-
say to detect extensive intestinal metaplasia was 36.4%, very low 
in this study. 
A high percentage of GC patients in Ardabil have normal level 
of pepsinogen I and a pepsinogen I to II ratio. This can mean that 
ahigh number of GC patients in this area had no remarkable pre-
cancerous conditions as observed in some countries. Genta et al. 
have found normal gastric mucosa in a quarter of the patients with 
GC in Switzerland.26 This fact may diminish the importance of the 
measurement of serum biomarkers in areas where the proportion 
of GC with no advanced AG is quite high.
In the group with subjects older than 60 years that were selected 
from orthopedic wards, the possibility of increased pepsinogens 
in their sera due to NSAIDS intake could not be excluded. How-
ever, as all subjects in this age group were mostly from the ortho-
pedic wards of hospitals in the three cities, the pepsinogen levels 
were compared and evaluated together.  
In conclusion, identifying the proportion of AG in at-risk popu-
lations is not possible by the pepsinogen I level and ratio of pep-
sinogen I to II in this area, as claimed by Kekki et al.27 The low 
sensitivity of serum biomarkers for the diagnosis of AG has been 
con¿rmed by other authors, as well.28–31 Furthermore, GC could 
occur in some areas with no necessary development of precancer-
ous conditions.
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